← Back

Elekta AB ser. B

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Elekta Care, a personalized services for radiotherapy suites. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Elekta Geneva, an applicator for cervical cancer patients; and Elekta Xoft Axxent electronic brachytherapy systems. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning; Elekta Care Community, a self-help center; and Elekta Partner Community, an online self-service portal. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Price · split & dividend adjusted
News & notes moving 0O5H.LSE
Biotech & Genomic Medicine2

Radiotherapy Market to Reach USD 10.68 Billion by 2031 at 6.0% CAGR

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.
GlobeNewswire·35dRead more ▾